InvestorsHub Logo
Followers 14
Posts 733
Boards Moderated 0
Alias Born 12/09/2013

Re: linhdtu post# 529

Tuesday, 08/05/2014 9:18:46 PM

Tuesday, August 05, 2014 9:18:46 PM

Post# of 2958

Abbvie knows how to price drugs as well as Gilead, and they have the benefit of Gilead pricing it's regimen first. Pricing the 3-D after Gilead sets prices will be a huge benefit, IMHO.
=========

BY the way.....
Somewhat off topic, but I cannot find a breakdown of Gilead cure rates contrasting genotype 1-A and 1B SVR rates (for any groups-naives, past TX failures, cirrhotics, etc). They all seem to be blended aggregate percentages.
Anyone seen a breakdown? Not in any Gilead disclosures I've seen.

~W
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News